Fig. 1

Patient disposition. ^aReasons for refusal for seven patients: incomplete information on hereditary angioedema (HAE) attacks 6 months before access request (n = 3); stable with no recent attacks (n = 2); insufficient patient information (n = 1); acquired angioedema (n = 1). ^bOne patient with acquired angioedema; one patient (with HAE-1) aged < 12 years. ^cLanadelumab was initiated (D0) on average ~ 46.5 days after the treatment access request; and follow-ups were counted from D0, not from Authorization for Temporary Use (ATU) entry. By the September 23, 2019, data freeze, not all patients had reached the 6 month follow-up period, or data for these patients were incomplete. AE adverse event, cATU ATU in a cohort, D day, nATU nominative ATU, q2wks every 2 weeks, q3wks every 3 weeks, q4wks every 4 weeks